<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04789148</url>
  </required_header>
  <id_info>
    <org_study_id>2020P003071</org_study_id>
    <nct_id>NCT04789148</nct_id>
  </id_info>
  <brief_title>Effects of Intranasal Oxytocin in Patients With Central Diabetes Insipidus</brief_title>
  <official_title>Effects of Intranasal Oxytocin in Patients With Central Diabetes Insipidus - A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Elizabeth Austen Lawson</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled crossover pilot study of single-dose&#xD;
      intranasal oxytocin (4 IU and 24 IU) in 18-60-year-old men and women with central diabetes&#xD;
      insipidus to evaluate the effect of oxytocin on anxiety, depression and socioemotional&#xD;
      functioning.&#xD;
&#xD;
      Following a screening visit to determine eligibility, participants will return for three main&#xD;
      study visits. During the main study visits, study participants will receive either oxytocin&#xD;
      or placebo, followed by assessments of emotional behavior.&#xD;
&#xD;
      Thirty participants will be equally randomized to one of six possible drug orders:&#xD;
&#xD;
        1. 4 IU oxytocin - 24 IU oxytocin - placebo&#xD;
&#xD;
        2. 4 IU oxytocin - placebo - 24 IU oxytocin&#xD;
&#xD;
        3. 24 IU oxytocin - 4 IU oxytocin - placebo&#xD;
&#xD;
        4. 24 IU oxytocin - placebo - 4 IU oxytocin&#xD;
&#xD;
        5. placebo - 4 IU oxytocin - 24 IU oxytocin&#xD;
&#xD;
        6. placebo - 24 IU oxytocin - 4 IU oxytocin&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dot-probe task - anxious behavior between low dose oxytocin and placebo</measure>
    <time_frame>20 minutes following intervention at each main visit</time_frame>
    <description>Difference in response times (in milliseconds) to dots appearing in the location of the previously shown negative versus the neutral face between 4 IU oxytocin vs placebo in the dot-probe task.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dot-probe task - anxious behavior between all three interventions</measure>
    <time_frame>20 minutes following intervention</time_frame>
    <description>Difference in response time (in milliseconds) to dots appearing in the location of the previously shown negative versus neutral face between 4 IU oxytocin, 24 IU oxytocin, and placebo in the dot-probe task.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depressive behavior - probabilistic reward task between all three interventions</measure>
    <time_frame>30 minutes following intervention at each main visit</time_frame>
    <description>Response bias developed toward the more frequently reinforced alternative between 4 IU oxytocin, 24 IU oxytocin, and placebo in the probabilistic reward task.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Socioemotional functioning - Emotion recognition task between all three interventions</measure>
    <time_frame>40 minutes following intervention at each main visit</time_frame>
    <description>Accuracy in identifying correct emotion between 4 IU oxytocin, 24 IU oxytocin, and placebo in the emotion recognition task.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Central Diabetes Insipidus</condition>
  <arm_group>
    <arm_group_label>4 IU oxytocin - 24 IU oxytocin - placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Main visit 1: 4 IU intranasal oxytocin; Main visit 2: 24 IU intranasal oxytocin; Main visit 3: intranasal placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4 IU oxytocin - placebo - 24 IU oxytocin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Main visit 1: 4 IU intranasal oxytocin; Main visit 2: intranasal placebo; Main visit 3: 24 IU intranasal oxytocin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>24 IU oxytocin - 4 IU oxytocin - placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Main visit 1: 24 IU intranasal oxytocin; Main visit 2: 4 IU intranasal oxytocin; Main visit 3: intranasal placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>24 IU oxytocin - placebo - 4 IU oxytocin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Main visit 1: 24 IU intranasal oxytocin; Main visit 2: intranasal placebo; Main visit 3: 4 IU intranasal oxytocin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - 4 IU oxytocin - 24 IU oxytocin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Main visit 1: intranasal placebo; Main visit 2: 4 IU intranasal oxytocin; Main visit 3: 24 IU intranasal oxytocin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - 24 IU oxytocin - 4 IU oxytocin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Main visit 1: intranasal placebo; Main visit 2: 24 IU intranasal oxytocin; Main visit 3: 4 IU intranasal oxytocin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxytocin nasal spray</intervention_name>
    <description>4 IU intranasal oxytocin, 24 IU intranasal oxytocin or placebo</description>
    <arm_group_label>24 IU oxytocin - 4 IU oxytocin - placebo</arm_group_label>
    <arm_group_label>24 IU oxytocin - placebo - 4 IU oxytocin</arm_group_label>
    <arm_group_label>4 IU oxytocin - 24 IU oxytocin - placebo</arm_group_label>
    <arm_group_label>4 IU oxytocin - placebo - 24 IU oxytocin</arm_group_label>
    <arm_group_label>Placebo - 24 IU oxytocin - 4 IU oxytocin</arm_group_label>
    <arm_group_label>Placebo - 4 IU oxytocin - 24 IU oxytocin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Central diabetes insipidus (based on routine clinical practice, e.g., clinical&#xD;
             symptoms, serum and urinary sodium and osmolality levels or the water deprivation&#xD;
             test)&#xD;
&#xD;
          -  Normal FT4 or T4&#xD;
&#xD;
          -  Stable hormone replacement (no change in dose of hormone replacement in six weeks&#xD;
             prior to baseline)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active substance use disorder within the last 6 months&#xD;
&#xD;
          -  History of psychosis&#xD;
&#xD;
          -  Current suicidal ideation&#xD;
&#xD;
          -  Medication changes within 4 weeks of enrollment or during the study&#xD;
&#xD;
          -  History of cardiac disease, including arrhythmias, coronary heart disease, coronary&#xD;
             artery spasms, valvular heart disease, hypertrophic cardiomyopathy (hypertension is&#xD;
             not exclusionary)&#xD;
&#xD;
          -  Hyponatremia&#xD;
&#xD;
          -  Creatinine &gt;1.5mg/dL.&#xD;
&#xD;
          -  ALT or AST &gt;2.5x upper limit of normal&#xD;
&#xD;
          -  Hematocrit less than 2% below the norm&#xD;
&#xD;
          -  Pregnancy or breastfeeding within the last 8 weeks&#xD;
&#xD;
          -  Unwilling to use a medically acceptable form of contraception throughout the study&#xD;
             period (female of child-bearing potential only)&#xD;
&#xD;
          -  Received an investigational drug or medical device in the past 30 days or within 5&#xD;
             half-lives of main study visit or be concurrently enrolled in another investigational&#xD;
             product clinical trial.&#xD;
&#xD;
          -  Any significant illness or condition that the Investigator determines could interfere&#xD;
             with study participation, data collection, or safety&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elizabeth A Lawson, MD, MMSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elizabeth A Lawson, MD, MMSc</last_name>
    <phone>(617) 726-3870</phone>
    <email>ealawson@partners.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Clara O Sailer, MD, PhD</last_name>
    <phone>617-724-2510</phone>
    <email>cosailer@mgh.harvard.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Massachusetts General Hospital, Neuroendocrine Unit</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Elizabeth A Lawson, MD, MMSc</last_name>
      <phone>617-726-3870</phone>
      <email>ealawson@partners.org</email>
    </contact>
    <contact_backup>
      <last_name>Clara O Sailer, MD, PhD</last_name>
      <phone>617-724-2510</phone>
      <email>cosailer@mgh.harvard.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>March 5, 2021</study_first_submitted>
  <study_first_submitted_qc>March 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 9, 2021</study_first_posted>
  <last_update_submitted>November 7, 2021</last_update_submitted>
  <last_update_submitted_qc>November 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Elizabeth Austen Lawson</investigator_full_name>
    <investigator_title>Associate Professor of Medicine, Harvard Medical School; Director, Interdisciplinary Oxytocin Research Program, Neuroendocrine Unit, Massachusetts General Hospital</investigator_title>
  </responsible_party>
  <keyword>Hypopituitarism</keyword>
  <keyword>posterior pituitary</keyword>
  <keyword>oxytocin</keyword>
  <keyword>psychopathology</keyword>
  <keyword>anxiety</keyword>
  <keyword>depressive symptoms</keyword>
  <keyword>socioemotional functioning</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Insipidus</mesh_term>
    <mesh_term>Diabetes Insipidus, Neurogenic</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

